whitepaper

ebook: Optimise your high value cell lines

Posted: 30 June 2021 | | No comments yet

As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.

During the last decade, production of monoclonal antibodies (mAbs) and recombinant proteins using mammalian cells has led to a boom in the introduction of biotherapeutic proteins to the market. In this ebook, we present an overview of the cell line development workflow as well as high throughput solutions for accelerating the process, and enabling easier and faster selection of high-producing mammalian cell lines.












    To read this ebook in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Molecular Devices

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend